Pharmaceutical: The problem of manipulated data

TRADELABOR has more than 20 years of experience in the control and treatment of air, working with an experienced and qualified technical staff and with the most advanced technology in this area, which together guarantee the quality of the services provided.



In August, the FDA accused Novartis of submitting a drug application with manipulated data and then not informing regulators of the issue until a month after approval. According to the FDA, the company was aware of the issues two months before the FDA greenlighted Zolgensma. Abi Millar asks how this situation came about and what more can be done.

Continue at:

The text above is owned by the site above referred.

Here is only a small part of the article, for more please follow the link

Also see:


Manostaxx – Industrial Management Consulting

Leave a Reply

Your email address will not be published. Required fields are marked *